BOSTON— Mispro, a provider of contract vivarium (CV) space and services, announced the opening of its eighth facility in the Boston area, located within the Southline Boston life sciences campus in Dorchester.
This expansion cements Mispro’s position as the region’s most deeply embedded vivarium partner, supporting the rapid preclinical growth of biotech companies across Greater Boston.
The new vivarium, slated to open in October 2025, brings Mispro’s proven CV model into a key innovation hub. Situated inside Southline’s 700,000+ square foot campus—a vibrant center for life sciences—Mispro’s presence will offer seamless access to in vivo research space for early- and growth-stage biotech companies.
“With each new facility, we’re investing in more than square footage—we’re expanding access to a smarter, de-risked model for in vivo research,” said Yohan Tessier, President & COO of Mispro. “The contract vivarium option reduces infrastructure burdens while keeping scientific control where it belongs— with the biotech teams driving discovery forward.”
The Southline facility further strengthens the support ecosystem for companies backed by Portal Innovations, an early-stage venture firm and incubator also located on campus.
“Having Mispro onsite brings in vivo capacity directly into the heart of our ecosystem,” said Tatiana Yglesias, Executive Director for Portal Boston. “This streamlined access supports lean operations, accelerates timelines, protects IP, and meaningfully de-risks development—key advantages in today’s fast-moving and capital-conscious funding environment.”
As the first company to introduce the CV model to the Boston metro area, Mispro plays a vital role in enabling speed, scalability, and scientific integrity for biotechs pursuing preclinical programs. In 2025, 75% of biotech M&A activity has involved companies conducting studies in Mispro facilities—an indicator of the model’s strategic value.
Currently supporting 45 biotech companies in the Boston area, Mispro’s growth continues to mirror the region’s status as a global epicenter for life sciences innovation.
“This expansion reflects our commitment to enabling science that moves—not just forward, but faster,” added Tessier.
